EcoDrugPlus

V-Akt Murine Thymoma Viral Oncogene Homolog 3a

Ensembl ID : ENSLCAG00010012110
Gene Symbol: AKT3A
4 Cross references
203 Possible Orthologues:

V-Rel Avian Reticuloendotheliosis Viral Oncogene Homolog A

Ensembl ID : ENSLCAG00010010220
Gene Symbol: RELA
1 Cross references
199 Possible Orthologues:

V-Src Avian Sarcoma (Schmidt-Ruppin A-2) Viral Oncogene Homolog

Ensembl ID : ENSLCAG00010025877
Gene Symbol: SRC
4 Cross references
197 Possible Orthologues:

Vascular Endothelial Growth Factor Aa

Ensembl ID : ENSLCAG00010003539
Gene Symbol: VEGFAA
4 Cross references
181 Possible Orthologues:

Vascular Endothelial Growth Factor Ab

Ensembl ID : ENSLCAG00010017988
Gene Symbol: VEGFAB
1 Cross references
201 Possible Orthologues:

Vitamin D Receptor

Ensembl ID : ENSLCAG00010008096
Gene Symbol: VDR
4 Cross references
388 Possible Orthologues:

Vitamin D3 Receptor B

Ensembl ID : ENSLCAG00010003182
Gene Symbol: LOC108884043
4 Cross references
392 Possible Orthologues:

Vitamin K Epoxide Reductase Complex, Subunit 1

Ensembl ID : ENSLCAG00010027504
Gene Symbol: VKORC1
1 Cross references
190 Possible Orthologues:

Voltage-Dependent Calcium Channel Gamma-4 Subunit

Ensembl ID : ENSLCAG00010013862
Gene Symbol: LOC108880070
4 Cross references
189 Possible Orthologues:

Voltage-Dependent Calcium Channel Gamma-6 Subunit

Ensembl ID : ENSLCAG00010024577
Gene Symbol: LOC108886966
4 Cross references
182 Possible Orthologues:

Xanthine Dehydrogenase

Ensembl ID : ENSLCAG00010025355
Gene Symbol: XDH
1 Cross references
208 Possible Orthologues:

Ensembl ID : ENSLCAG00010023263
Gene Symbol: -
1 Cross references
211 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).